Feedback
Settings

Settings

Goto Application

276 results
Offices all Languages Stemming true Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61M1/00 AND EN_ALLTXT:(coronavirus OR coronaviruses OR coronaviridae OR coronavirinae OR orthocoronavirus OR orthocoronaviruses OR orthocoronaviridae OR orthocoronavirinae OR betacoronavirus OR betacoronaviruses OR betacoronaviridae OR betacoronavirinae OR sarbecovirus OR sarbecoviruses OR sarbecoviridae OR sarbecovirinae OR "severe acute respiratory syndrome" OR sars OR "2019 ncov" OR covid)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 28
1.WO/2021/243372CLOSED-LOOP ANTIMICROBIAL PHOTO-PLASMAPHERESIS
WO - 02.12.2021
Int.Class A61M 1/36
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
1Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
36Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation
 Appl.No PCT/US2021/070633 Applicant BAYLOR COLLEGE OF MEDICINE Inventor SZIGETI, Reka
The present disclosure concerns systems and methods related to the treatment, prevention, delay of onset, or reduction of severity of a microbial infection in an individual, including closed-loop plasmapheresis and extracorporeal light irradiation of the plasma of the individual. The systems and methods further relate to irradiation of the plasma of the individual with UV and/or visible light, optionally in the presence of a photosensitizer. The systems and methods further relate to light irradiation inactivation of microbial particles in the plasma taken from the individual. The systems and methods further relate to the optional filtration of microbial particles from UV light-treated plasma. The systems and methods further relate to reinfusion of the UV light-treated, optionally filtered, plasma back into the individual. The systems and methods further relate to treating, preventing, delaying onset of, or reducing in severity a viral infection, particularly a viral infection caused by a Coronaviridae family virus, at least including SARS-CoV-2. The systems and methods are further configured to reduce viral load and/or lymphocyte reinfection rate in the individual.
2.WO/2023/064753DEVICES AND METHODS FOR TREATING A VIRAL INFECTION AND SYMPTOMS THEREOF
WO - 20.04.2023
Int.Class G01N 33/543
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
543with an insoluble carrier for immobilising immunochemicals
 Appl.No PCT/US2022/077885 Applicant AETHLON MEDICAL, INC. Inventor FISHER, JR., Charles J.
The devices and methods of the present invention can be used to capture and remove COVID-19 mediating nanoparticles and/or exosomes associated with COVID-19 or similar disease from the circulatory system of patients in need thereof, including those with post COVID-19 syndrome or similar post-disease sequelae symptoms of COVID-19 or similar disease. The present invention provides a lectin based extracorporeal methods for binding and physically removing SARS-CoV-2 virions, or fragments thereof such as SARS-Co V-2-derived glycoproteins, from the circulatory system, thereby reducing viral load in infected blood. The present invention also provides lectin based extracorporeal methods of binding and physically removing non-viral COVID-19 mediating nanoparticles, such as exosomes containing SARS-Co V-2-derived glycoproteins and/or other biological molecules from the circulatory system, thereby reducing the severity of the disease.
3.WO/2021/203015METHODS OF TREATING CONDITIONS
WO - 07.10.2021
Int.Class A61M 1/36
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
1Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
36Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation
 Appl.No PCT/US2021/025602 Applicant NATIONAL JEWISH HEALTH Inventor HIRSCH, Glenn, A.
The present disclosure relates to a method of treating conditions and/or diseases using blood irradiation. Conditions and diseases include cytokine storm syndrome, autoimmune diseases, and infectious diseases. The disclosure also relates to modulation of the immune system, for example by modulating leukocytes. The method involves removal of blood, exposing the removed blood to radiation, and placing the exposed blood into a patient. Radiation includes ultraviolet radiation and other types of radiation.
4.20230158222DEVICES AND METHODS FOR TREATING A CORONAVIRUS INFECTION AND SYMPTOMS THEREOF
US - 25.05.2023
Int.Class A61M 1/34
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
1Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
34Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration, diafiltration
 Appl.No 17918085 Applicant Aethlon Medical, Inc. Inventor Charles J. FISHER, Jr.

The devices and methods of the present invention can be used to capture and remove COVID-19 mediating nanoparticles and/or exosomes associated with COVID-19 or similar disease from the circulatory system of patients in need thereof, including those with post-COVID-19 syndrome or similar post-disease sequelae so-called “long haul” symptoms of COVID-19 or similar disease. The present invention benefits patients by providing lectin based extracorporeal methods for binding and physically removing SA RS-C7oV-2 virions, or fragments thereof, from the circulatory system. Also provided are lectin based extracorporeal methods of binding and physically removing non-viral COVID-19 mediating nanoparticles. Also disclosed herein are devices and methods for reducing the levels of biomarkers and markers of morbidity/mortality of diseases such as COVID-19 and similar diseases, including cytokines, such as IL-6, Troponin T, and D-dimer.

5.20220323345HUMANIZED ANTIBODY FOR SARS-CoV-2 SPIKE PROTEIN INFUSION
US - 13.10.2022
Int.Class A61K 9/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
 Appl.No 17717703 Applicant Arizona Board of Regents on behalf of Arizona State University Inventor Qiang Chen

An embodiment provides a method for treatment of the COVID-19 virus, including: preparing an intravenous infusion, wherein the intravenous infusion comprises at least one humanized monoclonal antibody against the SARS-CoV-2 spike protein; introducing the intravenous infusion to a patient; forming a virion antibody complex, wherein the virion antibody comprises the at least one humanized monoclonal antibody against the SARS-CoV-2 spike protein; and monitoring the virion antibody complex from a sample of a body fluid. Other aspects are described and claimed.

6.20220110972APPARATUS AND METHOD FOR INACTIVATIVING VIRUSES AND PATHOGENS IN CONVALESCENT PLASMA UNITS FROM RECOVERED COVID-19 PATIENTS
US - 14.04.2022
Int.Class A61K 35/16
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
16Blood plasma; Blood serum
 Appl.No 17499792 Applicant Trevor Percival Castor Inventor Trevor Percival Castor

The novel coronavirus COVID-19 has caused a worldwide pandemic of enormous proportions resulting in significant levels of morbidity and mortality, tremendous pressures on the healthcare system, personal freedoms and society, and an unprecedented impact on the economies of the United States and the world. There are still significant unknowns about this very contagious and deadly virus, and these unknowns are coupled with no natural immunity. A promising therapeutic strategy is the utilization/transfusion of convalescent plasma from recovered COVID-19 patients. There are, however, risks involved in such transfusions from residual virus and other adventitious viruses and bacteria. These risks can be minimized by the pathogen clearance of convalescent plasma units in a hospital setting. There is an immediate need for the rapid pathogen inactivation/clearance of convalescent plasma units from recovered COVID-19 patients.

The present invention is a physical pathogen reduction and inactivation apparatus and method for controlling or eliminating transfusion-transmittable infections in convalescent plasma from recovered COVID-19 donors. The invention inactivates both nonenveloped and enveloped viruses as well as pathogenic bacteria and parasites in units of human plasma, while retaining the potency of natural biologically-active proteinaceous products in the pathogen-reduced plasma. The invention uses critical, near-critical or supercritical fluids for viral and pathogen reduction of units of donor blood plasma in blood bags. The apparatus is in the form of a transportable mobile unit, where it can be used in hospitals, blood banks, and medical facilities.

7.WO/2021/178964SYSTEMS AND METHODS FOR GENERATING IMMUNE RESPONSES IN SUBJECTS USING MICROCHANNEL DELIVERY DEVICES
WO - 10.09.2021
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
 Appl.No PCT/US2021/021377 Applicant AQUAVIT PHARMACEUTICALS, INC. Inventor CHANG, Sobin
The present invention provides a method for generating an immune response in a subject, comprising administering to the subject's skin an immunizing composition from a SARS-CoV-2 pathogen, wherein the composition is administered with a microneedle delivery device.
8.20200289534Method of treating, reducing, or alleviating a medical condition in a patient
US - 17.09.2020
Int.Class A61K 31/706
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7042Compounds having saccharide radicals and heterocyclic rings
7052having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
706containing six-membered rings with nitrogen as a ring hetero atom
 Appl.No 16861128 Applicant Gholam A. Peyman Inventor Gholam A. Peyman

A method of treating, reducing, or alleviating a medical condition in a patient is disclosed herein. The method includes administering to a patient in need thereof a biocompatible drug comprising one or more antiviral medications together with one or more cell pathway inhibitors dissolved in a non-toxic semifluorinated alkane, the patient having one or more respiratory tract inflammatory diseases, the one or more cell pathway inhibitors blocking an inflammatory response of inflamed tissue without inhibiting an immune response of the patient, and the semifluorinated alkane evaporating quickly upon administration to the patient so as to leave the biocompatible drug at a desired treatment location. The administration of the biocompatible drug to the patient treats the one or more respiratory tract inflammatory diseases, reduces the symptoms associated with the one or more respiratory tract inflammatory diseases, and/or alleviates one or more respiratory tract inflammatory diseases.

9.20220143292TREATING COVID-19 UTILIZING EXTRACORPOREAL RADIOFREQUENCY
US - 12.05.2022
Int.Class A61M 1/36
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
1Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
36Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation
 Appl.No 17520171 Applicant MARV ENTERPRISES LLC Inventor Mitchell S. Felder

An embodiment provides a method for treating a body fluid of a patient with Covid-19, including: removing the body fluid from a patient, wherein the body fluid comprises a Covid-19 targeted pathogenic antigen (TPA); applying a treatment to the body fluid, wherein the treatment comprises an antibody that joins with the Covid-19 targeted pathogenic antigen in the body fluid to form an antibody-TPA complex, wherein the antibody comprises a radiofrequency absorption enhancer forming an antibody-radio frequency enhancing moiety-virion complex (ARFVC); removing the ARFVC from the body fluid using a radiofrequency source; and returning the body fluid to the patient. Other aspects are described and claimed.

10.WO/2021/178582SYSTEMS AND METHODS FOR TREATING PATIENTS INFECTED WITH SARS-COV-2
WO - 10.09.2021
Int.Class C12N 7/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
 Appl.No PCT/US2021/020736 Applicant HDL THERAPEUTICS, INC. Inventor BREWER, Hollis Bryan, Jr.
The present specification describes methods and systems for treating a patient having a SARS-CoV-2 virus load greater than a predefined threshold. A patient is assessed to determine if the patient has the SARS-CoV-2 virus load greater than the predefined threshold. If the patient has the SARS-CoV-2 virus load greater than the predefined threshold, a volume of plasma is removed from the patient. In a plasma delipidation system, the volume of plasma is mixed with an extraction solvent to delipidate at least some of the SARS-CoV-2 viruses in the patient's SARS-CoV-2 virus load, thereby causing one or more modifications to the SARS-CoV-2 viruses. The extraction solvent is removed from the plasma and the plasma is administered with the at least some of the delipidated SARS-CoV-2 viruses to the patient.
# -